Recent Conferences
October 14, 2010
Fall Forum
July 8, 2010
Summer Forum
April 15, 2010
Spring Forum
October 14, 2009
Accelerating High-Value Healthcare
September 16, 2009
Next Steps Toward a Robust Comparative Effectiveness Research Enterprise
July 20, 2009
Establishing a National Health Insurance Exchange
June 11, 2009
Federal Strategies for Promoting Affordable Biologics: Follow-On Biologic Competition
April 29, 2009
Implementing Bundled Payments for Health Care Services
November 24, 2008
Medicare Delivery System Reform
October 2, 2008
Specialty Pharmaceuticals: Policy Solutions for Encouraging Access and Affordability
July 16, 2008
Managing Specialty Pharmaceuticals
June 4, 2008
"Road Testing" Electronic Medical Records
April 30, 2008
Innovation Workgroup
April 10, 2008
Payment and Delivery System Reform
November 29, 2007
Comparative Effectiveness Congressional Briefing
November 27, 2007
Overview of Cost Management Strategies
October 24, 2007
Coverage With Evidence Development
October 2, 2007
Value-Based Payment for Medical Technologies
September 18, 2007
Personalized Medicine Conference
July 25, 2007
Comparative Effectiveness: Stakeholder Perspectives
April 11, 2007
Post Marketing Surveillance
February 14, 2007
Comparative Effectiveness Research: Congressional Briefing
November 30, 2006
Comparative Effectiveness Forum
October 12, 2006
Coverage Policy in an Era of Personalized Medicine
July 13, 2006
Pharmaceutical Benefit Management
May 1, 2006
Methodology Standards
April 4, 2006
Technology Assessment
October 3, 2005
Promoting Appropriate Utilization
April 1, 2005
Evidence-Based Health Care System
July 16, 2004
Correcting Underuse in Health Care
September 16, 2009
Next Steps Toward a Robust Comparative Effectiveness Research Enterprise
The momentum behind efforts to expand the nation’s capacity to generate comparative effectiveness research (CER) has reached a critical stage. Most stakeholders concur that better evidence about quality and value will drive better clinical decision making and could potentially slow the rate of growth in health care spending. How evidence is developed, whether it is trusted, and how is used by patients, providers, and payers will ultimately determine the success of comparative effectiveness initiatives.
This Senior Policy Roundtable addressed how policymakers can invest in CER to achieve maximum value, including:
What research areas and infrastructure should we invest in first?
What is the right process and structure for coordination and oversight of research funding and disseminating results?
How can we ensure that results from CER are relevant, valuable and actionable for patients, physicians, and health care organizations?
